Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Robert Zirkelbach

Robert Zirkelbach Robert Zirkelbach is Executive Vice President of Public Affairs at PhRMA. He joined PhRMA in 2014 after working for seven years representing the health insurance industry. He likes Saturday afternoon BBQs on his deck, traveling, trying new restaurants, and attempting to play golf. He’s an avid, somewhat obsessive, Iowa Hawkeye fan and is lucky to have a wife that loves watching college football on Saturday afternoons.

Recent Posts

Why won’t the insurance industry tell the truth about medicine costs?

By Robert Zirkelbach  |    May 10, 2017
Discussions about the cost of medicines are important. We recognize that many patients are struggling to access the medicines they need, and we want to work with policymakers and other health care...   Read More

This is not a special effect: New video shows the destruction of a rogue cell

By Robert Zirkelbach  |    April 10, 2017
In the latest video of our Cells series, part of the GOBOLDLY™ campaign, we witness the destruction of a rogue cell that causes rheumatoid arthritis (RA), a disease that affects 1.3 million...   Read More

This is not a video game: New TV ad showcases the destruction of a cancer cell by immune system

By Robert Zirkelbach  |    February 5, 2017
Today, as part of our new advertising and public affairs initiative, GOBOLDLY™, we are excited to announce the premier of our newest TV advertisement, Cells, which highlights innovative...   Read More

Are insurers exaggerating medicine costs to justify premium increases? Consumers think so.

By Robert Zirkelbach  |    September 9, 2016
Despite recent headlines, U.S. spending on prescription medicines continues to decline. In fact, new data from Altarum Institute found that spending on prescription medicines grew by just 3.9...   Read More

CSRxP proposals would undermine competitive market, harm patients and innovation

By Robert Zirkelbach  |    April 25, 2016
These so-called market-based proposals are nothing more than a litany of new government regulations and mandates that would undermine the competitive market and empower government bureaucrats and...   Read More

ICYMI: Policy solutions for delivering innovative treatments to patients

By Robert Zirkelbach  |    March 11, 2016
Yesterday, at the PhRMA 2016 Annual Meeting, PhRMA president and CEO Steve Ubl laid out his vision for the organization and released policy solutions for delivering innovative treatments to...   Read More

PhRMA Statement on Medicare Drug Spending Dashboard

By Robert Zirkelbach  |    December 21, 2015
The prescription drug spending data released by the Centers for Medicare & Medicaid Services (CMS) today provide a misleading and incomplete picture of actual Medicare spending on prescription...   Read More

What you need to know about access to innovative medicines in the U.S.

By Robert Zirkelbach  |    December 1, 2015
Today the Wall Street Journal published another story on prescription drug spending that cherry-picks Medicare Part B data in an effort to compare medicine prices in the U.S. to other countries....   Read More

6 things to know before the HHS forum

By Robert Zirkelbach  |    November 19, 2015
Tomorrow, the Department of Health and Human Services (HHS) will host a forum on pharmaceutical innovation, access, affordability and better health. We welcome the opportunity to discuss how we...   Read More

What makes Valeant different than innovative biopharmaceutical companies?

By Robert Zirkelbach  |    October 22, 2015
Much like Turing, Valeant Pharmaceutical’s strategy is more reflective of a hedge fund than an innovative biopharmaceutical company. Valeant’s CEO has stated that the company’s “strategy is quite...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates